Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

dc.authorid0000-0003-2137-7934en_US
dc.contributor.authorBremer, Birgit
dc.contributor.authorAnastasiou, Olympia E.
dc.contributor.authorHardtke, Svenja
dc.contributor.authorCaruntu, Florin Alexandru
dc.contributor.authorCurescu, Manuela G.
dc.contributor.authorYalçın, Kendal
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorGürel, Selim
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorErhardt, Andreas
dc.contributor.authorLuth, Stefan
dc.contributor.authorPapatheodoridis, George, V.
dc.contributor.authorRadu, Monica
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorManns, Michael P.
dc.contributor.authorCornberg, Markus
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorWedemeyer, Heiner
dc.date.accessioned2021-04-27T11:20:12Z
dc.date.available2021-04-27T11:20:12Z
dc.date.issued2020en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç HastalıklarAna Bilim Dalıen_US
dc.descriptionWOS:000595714300001
dc.descriptionPMID: 33217778
dc.description.abstractThe role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.en_US
dc.identifier.citationBremer, B., Anastasiou, O.E., Hardtke, S., Caruntu, F.A., Curescu, M.G., Yalçın, K. ve diğerleri. (2020). Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver International, 41(2), 295-299.en_US
dc.identifier.doi10.1111/liv.14740
dc.identifier.endpage299en_US
dc.identifier.issn1478-3223
dc.identifier.issn1478-3231
dc.identifier.issue2en_US
dc.identifier.pmid33217778
dc.identifier.scopus2-s2.0-85097085763
dc.identifier.scopusqualityQ1
dc.identifier.startpage295en_US
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.14740
dc.identifier.urihttps://hdl.handle.net/11468/6814
dc.identifier.volume41en_US
dc.identifier.wosWOS:000595714300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYalçın, Kendal
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofLiver International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHDVen_US
dc.subjectHepatitis Den_US
dc.subjectPCRen_US
dc.subjectRelapseen_US
dc.subjectResidual viraemiaen_US
dc.titleResidual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II studyen_US
dc.titleResidual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Residual low HDV viraemia is associated HDV RNA relapse.pdf
Boyut:
410.7 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: